169 related articles for article (PubMed ID: 26182862)
1. [China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)].
Shi Y; Sun Y; Ding C; Wang Z; Wang C; Wang Z; Bai C; Bai C; Feng J; Liu X; Li F; Yang Y; Shu Y; Wu M; He J; Zhang Y; Zhang S; Chen G; Luo H; Luo R; Zhou C; Zhou Y; Pang Q; Zhao H; Zhao Q; Gu A; Ling Y; Huang C; Han B; Jiao S; Jian H
Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):397-400. PubMed ID: 26182862
[No Abstract] [Full Text] [Related]
2. [China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment
(2016 version)].
Shi Y; Sun Y; Ding C; Wang Z; Wang C; Bai C; Bai C; Feng J; Liu X; Li F; Yang Y; Shu Y; Wu M; He J; Zhang Y; Zhang S; Chen G; Luo H; Luo R; Zhou C; Pang Q; Hu X; Zhao H; Zhao Q; Gu A; Ling Y; Huang C; Han B; Jiao S; Jian H
Zhongguo Fei Ai Za Zhi; 2016 Jul; 19(7):489-94. PubMed ID: 27339727
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Lu S; Ye M; Ding L; Tan F; Fu J; Wu B
Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283
[TBL] [Abstract][Full Text] [Related]
4. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
5. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y
Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
[TBL] [Abstract][Full Text] [Related]
6. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
[TBL] [Abstract][Full Text] [Related]
7. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
[TBL] [Abstract][Full Text] [Related]
8. Icotinib: activity and clinical application in Chinese patients with lung cancer.
Guan YS; He Q; Li M
Expert Opin Pharmacother; 2014 Apr; 15(5):717-28. PubMed ID: 24588695
[TBL] [Abstract][Full Text] [Related]
9. [Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].
Ren YL; Sheng J; Zhou XY; Fang Y; Pan HM
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):152-153. PubMed ID: 30862147
[No Abstract] [Full Text] [Related]
10. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
Tan F; Shi Y; Wang Y; Ding L; Yuan X; Sun Y
Future Oncol; 2015; 11(3):385-97. PubMed ID: 25675121
[TBL] [Abstract][Full Text] [Related]
11. Icotinib: kick-starting the Chinese anticancer drug industry.
Camidge DR
Lancet Oncol; 2013 Sep; 14(10):913-4. PubMed ID: 23948350
[No Abstract] [Full Text] [Related]
12. [Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].
Li X; Yang XJ; Sun YF; Qin N; Lü JL; Wu YH; Zhang H; Zhang Q; Zhang SC
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):627-31. PubMed ID: 23159001
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
Biaoxue R; Hua L; Wenlong G; Shuanying Y
Oncotarget; 2016 Dec; 7(52):86902-86913. PubMed ID: 27893423
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
[TBL] [Abstract][Full Text] [Related]
15. Influence of wellness education on first-line icotinib hydrochloride patients with stage IV non-small cell lung cancer and their family caregivers.
Yanwei L; Minghui F; Manman Q; Zhuchun Y; Dongying L; Zhanyu P
Curr Probl Cancer; 2018; 42(3):358-366. PubMed ID: 29731164
[TBL] [Abstract][Full Text] [Related]
16. Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.
Gong L; Xiong M; Huang Z; Miao L; Fan Y
Lung Cancer; 2015 Sep; 89(3):268-73. PubMed ID: 26141219
[TBL] [Abstract][Full Text] [Related]
17. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
Li X; Qin N; Wang J; Yang X; Zhang X; Lv J; Wu Y; Zhang H; Nong J; Zhang Q; Zhang S
Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):734-9. PubMed ID: 26706949
[TBL] [Abstract][Full Text] [Related]
18. Medicine. Why a new cancer drug works well, in some patients.
Marx J
Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
[No Abstract] [Full Text] [Related]
19. [Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Shi YK
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):398-400. PubMed ID: 22883466
[No Abstract] [Full Text] [Related]
20. Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer.
Zhu C; You YH; Nie KK; Ji YX
Chin Med J (Engl); 2019 May; 132(9):1115-1116. PubMed ID: 31033571
[No Abstract] [Full Text] [Related]
[Next] [New Search]